Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression

American Journal of Pathology

Volumn 162, Issue 6, 2003, Pages 1789-1806

  Acs, Geza ^a   Zhang, Paul J ^a   McGrath, Cindy M ^a   Acs, Peter ^b   McBroom, John ^c   Mohyeldin, Ahmed ^d   Liu, Suzhen ^d   Lu, Huasheng ^d   Verma, Ajay ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Huron Hospital   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GENISTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CYTOTOXICITY; DYSPLASIA; HELA CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

EID: 0038751965     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64314-3     Document Type: Article

References (127)

1. Rose PG: Chemoradiotherapy for cervical cancer. Eur J Cancer 2002, 38:270-278
2. Advances in the treatment of cervical cancer. International Network for Cancer Treatment and Research, Brussels, Belgium, 20 April, 2001 Meeting
3. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999, 49:31-64
4. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999, 80:827-841
5. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7-33
6. Wright TC, Ferenczy A, Kurman RJ: Carcinoma and other tumors of the cervix. Blaustein's Pathology of the Female Genital Tract. Edited by RJ Kurman. New York, Springer, 2002, pp 325-381
7. Milde-Langosch K, Riethdorf S, Loning T: Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications. Virchows Arch 2000, 437:227-233
8. Schiffman MH, Brinton LA: The epidemiology of cervical carcinogenesis. Cancer 1995, 76:1888-1901
9. Kurman RJ, Norris HJ, Wilkinson EJ: Tumors of the Cervix, Vagina, and Vulva. Washington DC, Armed Forces Institute of Pathology, 1992
10. Park TW, Fujiwara H, Wright TC: Molecular biology of cervical cancer and its precursors. Cancer 1995, 76:1902-1913
11. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989, 63:4417-4421
12. Huibregtse JM, Scheffner M, Howley PM: A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991, 10:4129-4135
13. Dyson N, Guida P, Munger K, Harlow E: Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992, 66:6893-6902
14. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
15. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756
16. Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994, 54:6078-6082
17. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M: Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001, 92:276-284
18. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T: Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998, 153:1741-1748
19. Kerr JF, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73:2013-2026
20. Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 1991, 65:1097-1098
21. Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, Chadwick C, Wilks DP, Potten CS, Hendry JH, Hunter RD: Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995, 37:1-9
22. Sheets EE, Yeh J: The role of apoptosis in gynaecological malignancies. Ann Med 1997, 29:121-126
23. Dellas A, Schultheiss E, Holzgreve W, Oberholzer M, Torhorst J, Gudat F: Investigation of the Bcl-2 and C-myc expression in relationship to the Ki-67 labelling index in cervical intraepithelial neoplasia. Int J Gynecol Pathol 1997, 16:212-218
24. Saegusa M, Takano Y, Hashimura M, Shoji Y, Okayasu I: The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer 1995, 76:2297-2303
25. ter Harmsel B, Kuijpers J, Smedts F, Jeunink M, Trimbos B, Ramaekers F: Progressing imbalance between proliferation and apoptosis with increasing severity of cervical intraepithelial neoplasia. Int J Gynecol Pathol 1997, 16:205-211
26. Höckel M, Schlenger K, Knoop C, Vaupel P: Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991, 51:6098-6102
27. Vaupel P, Kelleher DK, Höckel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001, 28:29-35
28. Vaupel P, Schlenger K, Knoop C, Höckel M: Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991, 51:3316-3322
29. Moulder JE, Rockwell S: Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Rad Oncol Biol Phys 1984, 10:695-712
30. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465
31. Höckel M, Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol 2001, 28:36-41
32. Höckel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276
33. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56:4509-4515
34. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998, 48:149-156
35. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416
36. Dachs GU, Chaplin DJ: Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Rad Oncol 1998, 8:208-216
37. Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P: Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26:45-50
38. Höckel M, Schlenger K, Höckel S, Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999, 59:4525-4528
39. Semenza GL: Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res 2001, 49:614-617
40. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845
41. Moritz KM, Lim GB, Wintour EM: Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 1997, 273:R1829-R1844
42. Stopka T, Zivny JH, Stopkova P, Prchal JF, Prchal JT: Human hematopoietic progenitors express erythropoietin. Blood 1998, 91:3766-3772
43. Jelkmann W: Biology of erythropoietin. Clin Invest 1994, 72:S3-S10
44. Ebert BL, Bunn HF: Regulation of the erythropoietin gene. Blood 1999, 94:1864-1877
45. Ratcliffe PJ, Ebert BL, Firth JD, Gleadle JM, Maxwell PH, Nagao M, O'Rourke JF, Pugh CW, Wood SM: Oxygen regulated gene expression: erythropoietin as a model system. Kidney Int 1997, 51:514-526
46. Lacombe C, Mayeux P: The molecular biology of erythropoietin. Nephrol Dial Transplant 1999, 14:22-28
47. Koury MJ, Bondurant MC: The molecular mechanism of erythropoietin action. Eur J Biochem 1992, 210:649-663
48. Ihle JN, Thierfelder W, Teglund S, Stravapodis D, Wang D, Feng J, Parganas E: Signaling by the cytokine receptor superfamily. Ann NY Acad Sci 1998, 865:1-9
49. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O: Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995, 13:369-398
50. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Thierfelder WE, Kreider B, Silvennoinen O: Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994, 19:222-227
51. Klingmuller U: The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells - signals emanating from the erythropoietin receptor. Eur J Biochem 1997, 249:637-647
52. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ: Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999, 253:143-156
53. Tilbrook PA, Klinken SP: The erythropoietin receptor. Int J Biochem Cell Biol 1999, 31:1001-1005
54. Tilbrook PA, Klinken SP: Erythropoietin and erythropoietin receptor. Growth Factors 1999, 17:25-35
55. Chin H, Nakamura N, Kamiyama R, Miyasaka N, Ihle JN, Miura O: Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood 1996, 88:4415-4425
56. Miura Y, Miura O, Ihle JN, Aoki N: Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 1994, 269:29962-29969
57. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL: Erythrepoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999, 274:22165-22169
58. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL: Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996, 88:1576-1582
59. Gobert S, Duprez V, Lacombe C, Gisselbrecht S, Mayeux P: The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem 1995, 234:75-83
60. Vogt C, Pentz S, Rich IN: A role for the macrophage in normal hemopoiesis: III. In vitro and in vivo erythropoietin gene expression in macrophages detected by in situ hybridization. Exp Hematol 1989, 17:391-397
61. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R: A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994, 269:19488-19493
62. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M: Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996, 8:666-676
63. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM: Expression of erythropoietin by the human placenta. EMBO J 1996, 10:760-768
64. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001, 61:3561-3565
65. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A: Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002, 95:969-981
66. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christensen RD: Origin and fate of erythropoietin in human milk. Pediatr Res 2000, 48:660-667
67. Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, Mori S, Matsuo T, Nakamura Y: Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001, 106:215-222
68. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R: Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998, 273:25381-25387
69. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994, 91:3974-3978
70. Juul SE, Anderson DK, Li Y, Christensen RD: Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998, 43:40-49
71. Fairchild Benyo D, Conrad KP: Expression of the erythropoietin receptor by trophoblast cells in the human placenta. Biol Reprod 1999, 60:861-870
72. Masuda S, Nagao M, Sasaki R: Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 1999, 70:1-6
73. Sasaki R, Masuda S, Nagao M: Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 2000, 64:1775-1793
74. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R: Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neurosci 1997, 76:105-116
75. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H: Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001, 101:271-276
76. Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y: Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996, 239:494-500
77. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990, 87:5978-5982
78. Mitjavila MT, Le Couedic JP, Casadevall N, Navarro S, Villeval JL, Dubart A, Vainchenker W: Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro. J Clin Invest 1991, 88:789-797
79. Westenfelder C, Baranowski RL: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000, 58:647-657
80. Assandri R, Egger M, Gassmann M, Niggli E, Bauer C, Forster I, Gorlach A: Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line. J Physiol 1999, 516:343-352
81. Wang GL, Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995, 270:1230-1237
82. Juul SE, Yachnis AT, Christensen RD: Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998, 52:235-249
83. Kim MJ, Bogic L, Cheung CY, Brace RA: Placental expression of erythropoietin mRNA, protein and receptor in sheep. Placenta 2001, 22:484-489
84. Ikegaya N, Yamamoto T, Takeshita A, Watanabe T, Yonemura K, Miyaji T, Ohishi K, Furuhashi M, Maruyama Y, Hishida A: Elevated erythropoietin receptor and transforming growth factor-beta1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol 2000, 11:928-935
85. Basil JB, Horowitz IR: Cervical carcinoma: contemporary management. Obstet Gynecol Clin North Am 2001, 28:727-742
86. Grigsby PW, Herzog TJ: Current management of patients with invasive cervical carcinoma. Clin Obstet Gynecol 2001, 44:531-537
87. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs III CL, Walker JL, Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999, 340:1154-1161
88. Wang GL, Semenza GL: Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol 1996, 3:156-162
89. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001, 61:2911-2916
90. Vukovic V, Haugland HK, Nicklee T, Morrison AJ, Hedley DW: Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001, 61:7394-7398
91. Colpaert C, Vermeulen P, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E: Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathol 2001, 39:416-425
92. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835
93. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000, 35:71-103
94. Haroon ZA, Raleigh JA, Greenberg CS, Dewhirst MW: Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann Surg 2000, 231:137-147
95. Ter Harmsel B, Smedts F, Kuijpers J, Jeunink M, Trimbos B, Ramaekers F: BCL-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma. J Pathol 1996, 179:26-30
96. Pallard C, Gouilleux, F, Charon M, Groner B, Gisselbrecht S, Dusanter-Fourt I: Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells. J Biol Chem 1995, 270:15942-15945
97. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Met Rev 1992, 11:121-139
98. Makin G, Hickman JA: Apoptosis and cancer chemotherapy. Cell Tissue Res 2000, 301:143-152
99. Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE: Apoptosis in irradiated murine tumors. Radiat Res 1991, 127:308-316
100. Levine EL, Davidson SE, Roberts SA, Chadwick CA, Potten CS, West CM: Apoptosis as predictor of response to radiotherapy in cervical carcinoma. Lancet 1994, 344:472
101. Makin G: Targeting apoptosis in cancer chemotherapy. Expert Opin Ther Targets 2002, 6:73-84
102. Makin G, Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 2001, 11:S22-S26
103. Zhivotovsky B, Joseph B, Orrenius S: Tumor radiosensitivity and apoptosis. Exp Cell Res 1999, 248:10-17
104. Verheij M, Bartelink H: Radiation-induced apoptosis. Cell Tissue Res 2000, 301:133-142
105. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, Ohyama T, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K, Takahashi T: Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 1996, 67:101-105
106. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M: BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996, 60:23-32
107. Kitada S, Krajewski S, Miyashita T, Krajewska M, Reed JC: Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 1996, 12:187-192
108. Kokawa K, Shikone T, Otani T, Nakano R: Transient increases of apoptosis and Bax expression occurring during radiotherapy in patients with invasive cervical carcinoma. Cancer 1999, 86:79-87
109. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995, 55:4471-4478
110. Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapak CA, Kufe D: Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 1995, 6:363-370
111. Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J, Friedrich E: Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002, 88:150-159
112. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA: Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002, 82:911-918
113. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, Nakamura Y: Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001, 84:836-843
114. Kim CY, Tsai MH, Osmanian C, Graeber TG, Lee JE, Giffard RG, DiPaolo JA, Peehl DM, Giaccia AJ: Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 1997, 57:4200-4204
115. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91
116. Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S, Herman B: Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995, 57:509-521
117. Littlewood TJ: The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001, 28:49-53
118. Kelleher DK, Matthiensen U, Thews O, Vaupel P: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996, 56:4728-4734
119. Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP: Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol 2000, 57:13-19
120. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B: Epoetin Alfa Study G: effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865-2874
121. Thatcher N: Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 1998, 25:23-26
122. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M, Bellorin-Font E: Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999, 55:546-553
123. Carlini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995, 47:740-745
124. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck K: Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002, 64:326-333
125. Ljungberg B, Rasmuson T, Grankvist K: Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol 1992, 21:160-163
126. Olujohungbe A, Handa S, Holmes J: Does erythropoietin accelerate malignant transformation in multiple myeloma? Postgrad Med J 1997, 73:163-164
127. Thomas G: The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 2001, 28:60-65